CR20170373A - Formulación en polvo nasal para el tratamiento de hipogligemia - Google Patents

Formulación en polvo nasal para el tratamiento de hipogligemia

Info

Publication number
CR20170373A
CR20170373A CR20170373A CR20170373A CR20170373A CR 20170373 A CR20170373 A CR 20170373A CR 20170373 A CR20170373 A CR 20170373A CR 20170373 A CR20170373 A CR 20170373A CR 20170373 A CR20170373 A CR 20170373A
Authority
CR
Costa Rica
Prior art keywords
powder formulation
treatment
hypogligemia
nasal powder
present
Prior art date
Application number
CR20170373A
Other languages
English (en)
Inventor
Sankaram B Matripragada
Claude A Piche
Betsbrugge Jo Jan Filip Van
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55538593&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20170373(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20170373A publication Critical patent/CR20170373A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0043—Non-destructive separation of the package, e.g. peeling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073—Syringe, piston type

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una formulación en polvo que contiene glucagón o un análogo de glucagón para administración nasal, útil en el tratamiento de hipoglicemia, y en particular el tratamiento de hipoglicemia severa. La presente invención también proporciona un método para elaborar esta formulación en polvo, y a dispositivos y métodos para usar la formulación en polvo.
CR20170373A 2015-02-17 2016-02-16 Formulación en polvo nasal para el tratamiento de hipogligemia CR20170373A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562117031P 2015-02-17 2015-02-17
PCT/US2016/018003 WO2016133863A1 (en) 2015-02-17 2016-02-16 Nasal powder formulation for treatment of hypoglycemia

Publications (1)

Publication Number Publication Date
CR20170373A true CR20170373A (es) 2017-09-18

Family

ID=55538593

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170373A CR20170373A (es) 2015-02-17 2016-02-16 Formulación en polvo nasal para el tratamiento de hipogligemia

Country Status (41)

Country Link
US (3) US10213487B2 (es)
EP (3) EP3673900A1 (es)
JP (3) JP6522144B2 (es)
KR (1) KR102121443B1 (es)
CN (1) CN107278154B (es)
AU (2) AU2016220235B2 (es)
BR (1) BR112017014994B1 (es)
CA (1) CA2975562C (es)
CL (1) CL2017002031A1 (es)
CO (1) CO2017008148A2 (es)
CR (1) CR20170373A (es)
CY (1) CY1122716T1 (es)
DK (1) DK3258919T4 (es)
DO (1) DOP2017000179A (es)
EA (1) EA034820B1 (es)
EC (1) ECSP17053843A (es)
ES (1) ES2775498T5 (es)
FI (1) FI3258919T4 (es)
GT (1) GT201700179A (es)
HR (1) HRP20200222T4 (es)
HU (1) HUE049413T2 (es)
IL (1) IL253273B (es)
LT (1) LT3258919T (es)
MA (3) MA52252A (es)
MD (1) MD3258919T3 (es)
MX (1) MX2017010572A (es)
MY (1) MY175669A (es)
NZ (1) NZ734035A (es)
PE (1) PE20171334A1 (es)
PH (1) PH12017501486A1 (es)
PL (1) PL3258919T5 (es)
PT (1) PT3258919T (es)
RS (1) RS59918B2 (es)
SA (1) SA517382068B1 (es)
SG (1) SG11201705640PA (es)
SI (1) SI3258919T2 (es)
SV (1) SV2017005515A (es)
TN (1) TN2017000349A1 (es)
UA (1) UA121874C2 (es)
WO (1) WO2016133863A1 (es)
ZA (2) ZA201704944B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3258919T4 (fi) * 2015-02-17 2023-02-09 Nasaalinen jauheformulaatio hypoglykemian hoitoon
US11013873B2 (en) * 2017-01-06 2021-05-25 HealthPartners Institite Methods for treating patients with impaired awareness of hypoglycemia
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
AU2018319592B2 (en) 2017-08-20 2024-06-27 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
SG11202002600VA (en) * 2017-09-21 2020-04-29 Scripps Research Inst Novel therapies for treating and preventing chronic rhinosinusitis
TWI771669B (zh) 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
CA3171184A1 (en) 2020-03-16 2021-09-23 Jesper Skodborg VILLADSEN Liquid formulations of glucagon analogues
CN115666513A (zh) 2020-05-18 2023-01-31 奥瑞克索股份公司 用于药物递送的新颖药物组合物
KR20240103005A (ko) 2021-11-25 2024-07-03 오렉쏘 에이비 아드레날린을 포함하는 약학적 조성물

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58189118A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd 経鼻投与製剤
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US5059587A (en) 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
EP0308181A1 (en) * 1987-09-14 1989-03-22 Novo Nordisk A/S Trans-mucosal delivery formulations and a method for preparation thereof
DK49791D0 (da) * 1991-03-20 1991-03-20 Novo Nordisk As Nasalt pulverpraeparat
DE19518810A1 (de) 1995-05-26 1996-11-28 Bayer Ag Nasal-Applikator
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
WO1999046055A1 (fr) 1998-03-10 1999-09-16 Valois S.A. Reservoir, procede de remplissage du reservoir et dispositif de distribution du produit fluide contenu dans le reservoir
EP1061947B1 (en) 1998-03-13 2004-06-16 Novo Nordisk A/S Stabilized aqueous glucagon solutions comprising detergents
ATE269103T1 (de) 1998-03-13 2004-07-15 Novo Nordisk As Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
FR2817847B1 (fr) 2000-12-08 2003-03-28 Tebro Dispositif de distribution de produit fluide ou pulverulent
US7722566B2 (en) 2003-10-09 2010-05-25 Shin Nippon Biomedical Laboratories, Ltd. Device to deliver a powdery medicine into nasal cavity
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
BRPI0620586A2 (pt) * 2005-12-02 2011-11-16 Nastech Pharm Co formulação farmacêutica aquosa para administração intranasal e uso de uma formulação farmacêutica aquosa para elaborar um medicamento
ATE520714T1 (de) 2007-06-15 2011-09-15 Zealand Pharma As Glucagonanaloga
BRPI0823376A2 (pt) 2008-12-15 2015-06-16 Zealand Pharma As Análagos de glucagon
BRPI0823377A2 (pt) 2008-12-15 2016-09-27 Zealand Pharma As análogos de glucagon
BRPI0823378A2 (pt) 2008-12-15 2019-09-24 Zealand Pharma As análogos de glucagon
KR101809024B1 (ko) 2009-07-13 2017-12-14 질랜드 파마 에이/에스 아실화 글루카곤 유사체
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
US9610329B2 (en) * 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
WO2011117417A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
MX2012014961A (es) 2010-06-24 2013-02-26 Zealand Pharma As Analogos de glucagon.
JP2015502380A (ja) 2011-12-23 2015-01-22 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CN104470569B (zh) 2012-06-28 2018-04-27 美国政府(由卫生和人类服务部的部长所代表) 用于疫苗和其它治疗试剂的鼻干粉递送***
FI124134B (en) 2012-07-02 2014-03-31 One Way Sport Oy Binding between a ski and a ski boot
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
FI3258919T4 (fi) * 2015-02-17 2023-02-09 Nasaalinen jauheformulaatio hypoglykemian hoitoon

Also Published As

Publication number Publication date
ECSP17053843A (es) 2017-11-30
MA52253A (fr) 2021-02-17
CN107278154B (zh) 2021-04-09
US20230302093A1 (en) 2023-09-28
JP6522144B2 (ja) 2019-05-29
US20190282666A1 (en) 2019-09-19
DK3258919T3 (da) 2020-03-23
MY175669A (en) 2020-07-03
SI3258919T2 (sl) 2023-01-31
MA41547B1 (fr) 2020-04-30
FI3258919T4 (fi) 2023-02-09
CL2017002031A1 (es) 2018-03-23
RS59918B1 (sr) 2020-03-31
PH12017501486A1 (en) 2018-01-15
US20180000904A1 (en) 2018-01-04
CA2975562A1 (en) 2016-08-25
HRP20200222T4 (hr) 2022-12-23
ZA201901241B (en) 2020-10-28
SV2017005515A (es) 2018-08-27
SI3258919T1 (sl) 2020-03-31
EP3673899A1 (en) 2020-07-01
IL253273B (en) 2019-08-29
MA52252A (fr) 2021-02-17
SA517382068B1 (ar) 2020-10-26
BR112017014994A2 (pt) 2018-03-20
EP3258919A1 (en) 2017-12-27
JP7094242B2 (ja) 2022-07-01
NZ734035A (en) 2019-06-28
ES2775498T5 (es) 2023-01-31
EP3673900A1 (en) 2020-07-01
DOP2017000179A (es) 2017-08-31
EP3258919B1 (en) 2020-01-15
CO2017008148A2 (es) 2017-11-30
WO2016133863A1 (en) 2016-08-25
PL3258919T5 (pl) 2023-02-27
PE20171334A1 (es) 2017-09-13
AU2016220235B2 (en) 2021-04-29
MD3258919T2 (ro) 2020-07-31
EA201791560A1 (ru) 2018-02-28
JP2019147817A (ja) 2019-09-05
TN2017000349A1 (en) 2019-01-16
EP3258919B2 (en) 2022-11-09
JP2018507852A (ja) 2018-03-22
AU2016220235A1 (en) 2017-07-20
SG11201705640PA (en) 2017-08-30
EA034820B1 (ru) 2020-03-25
PT3258919T (pt) 2020-03-26
DK3258919T4 (da) 2022-11-21
LT3258919T (lt) 2020-02-25
CA2975562C (en) 2020-04-28
KR20170103934A (ko) 2017-09-13
RS59918B2 (sr) 2023-01-31
KR102121443B1 (ko) 2020-06-10
HRP20200222T1 (hr) 2020-05-29
GT201700179A (es) 2018-11-23
IL253273A0 (en) 2017-08-31
JP2021107418A (ja) 2021-07-29
ES2775498T3 (es) 2020-07-27
CN107278154A (zh) 2017-10-20
MX2017010572A (es) 2017-12-07
BR112017014994B1 (pt) 2023-12-19
PL3258919T3 (pl) 2020-08-10
AU2021203035B2 (en) 2023-07-13
JP7362687B2 (ja) 2023-10-17
UA121874C2 (uk) 2020-08-10
MD3258919T3 (ro) 2023-04-30
HUE049413T2 (hu) 2020-09-28
ZA201704944B (en) 2021-05-26
CY1122716T1 (el) 2021-03-12
US10213487B2 (en) 2019-02-26
AU2021203035A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
CO2017008148A2 (es) Formulación en polvo nasal para el tratamiento de hipoglicemia
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
CL2016002971A1 (es) Combinación.
CL2017003151A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
MX2016008978A (es) Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
GT201700124A (es) Formulación de relación fija de insulina glargina/lixisenatida
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
EP3265115A4 (en) USE OF A PTHRP ANALOGUE TO REDUCE FRACTURE RISK
GB2540110A (en) Corneal inlay delivery devices and methods
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
IL261116A (en) A drug for the treatment of diabetic foot infections
BR112017012938A2 (pt) uso por via oral de uma composição e método para aprimorar a aparência da celulite
PH12017501979A1 (en) Pharmaceutical compound
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
MX2016013979A (es) Nuevas vias de administracion de insulina, analogos de insulina o derivados de insulina.
NZ725354A (en) Transdermal formulations of pergolide and uses thereof
EA201301341A1 (ru) Фармацевтическая композиция, обладающая панкреопротекторным действием, её применение для профилактики или лечения панкреатита и способ профилактики и лечения панкреатита
UA115417U (xx) Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі